<![CDATA[
What Are Senescent Cells?
Senescent cells are damaged or aged cells that have permanently stopped dividing but resist the normal process of programmed cell death (apoptosis). Instead of being cleared by the immune system, these cells accumulate in tissues throughout the body, secreting a toxic cocktail of inflammatory molecules, enzymes, and growth factors known as the senescence-associated secretory phenotype (SASP).
Scientists have given them a vivid and accurate nickname: “zombie cells.” They are no longer alive in the sense of performing useful function, yet they refuse to die—and in the process, they damage the healthy cells around them.
At St. George Hospital (Klinik St. Georg) in Bad Aibling, Germany, senolytic therapy is an important component of our longevity medicine program. Dr. Julian Douwes, Chief Medical Officer, explains: “The accumulation of senescent cells is one of the most actionable hallmarks of aging. If we can reduce the senescent cell burden, we can reduce the chronic inflammation that drives so many age-related diseases.”
How Zombie Cells Accumulate and Why It Matters
The Normal Role of Senescence
Cellular senescence is not inherently harmful. It originally evolved as a protective mechanism:
- Cancer prevention: When a cell sustains DNA damage that could lead to cancer, senescence halts its division, preventing tumor formation.
- Wound healing: Senescent cells temporarily appear during wound repair, secreting growth factors that promote tissue regeneration. They are then cleared by the immune system.
- Embryonic development: Senescence plays a role in normal tissue sculpting during embryonic development.
The problem is not senescence itself, but the accumulation of senescent cells when the immune system can no longer clear them efficiently.
Why Senescent Cells Accumulate With Age
- Immune aging (immunosenescence): The immune system’s ability to recognize and clear senescent cells declines with age, allowing them to persist and accumulate.
- Increased production: More cells become senescent over time due to accumulated DNA damage, telomere shortening, oxidative stress, and metabolic dysfunction.
- SASP-driven propagation: The inflammatory molecules secreted by existing senescent cells can push neighboring healthy cells into senescence—a contagion effect that accelerates accumulation.
The Damage Caused by Senescent Cell Accumulation
The SASP secreted by senescent cells includes:
- Pro-inflammatory cytokines: IL-6, IL-8, TNF-alpha—driving chronic low-grade inflammation (“inflammaging”)
- Matrix metalloproteinases (MMPs): Enzymes that degrade the extracellular matrix, contributing to tissue breakdown, skin aging, and joint degeneration
- Growth factors: VEGF and others that can promote tumor growth in the tissue microenvironment
- Chemokines: That recruit immune cells, perpetuating chronic inflammation
Diseases and conditions linked to senescent cell accumulation include:
- Atherosclerosis and cardiovascular disease
- Type 2 diabetes and insulin resistance
- Osteoarthritis and degenerative joint disease
- Osteoporosis
- Pulmonary fibrosis
- Neurodegenerative diseases (Alzheimer’s, Parkinson’s)
- Frailty and sarcopenia (muscle wasting)
- Cancer progression
- Skin aging
What Are Senolytics?
Senolytics are a class of compounds designed to selectively eliminate senescent cells while leaving healthy cells unharmed. The term was coined in 2015 by Drs. James Kirkland and Tamara Tchkonia at the Mayo Clinic, whose landmark research demonstrated that clearing senescent cells in mice extended healthspan and reduced age-related pathology (Zhu et al., Aging Cell, 2015).
The principle is elegant: senescent cells rely on specific anti-apoptotic (pro-survival) pathways to resist cell death. Senolytics target these survival mechanisms, tipping senescent cells over the edge into apoptosis while healthy cells—which do not depend on the same survival pathways—remain unaffected.
Key Senolytic Compounds
Dasatinib + Quercetin (D+Q)
The most studied senolytic combination:
- Dasatinib: A tyrosine kinase inhibitor (originally developed as a cancer drug) that targets senescent cell survival pathways, particularly in fat tissue and the vascular system.
- Quercetin: A natural flavonoid found in apples, onions, and berries that complements dasatinib by targeting senescent cells in other tissue types, particularly epithelial cells.
- Together: The combination targets a broader range of senescent cell types than either compound alone.
- Clinical evidence: The first human trial (Hickson et al., EBioMedicine, 2019) demonstrated that D+Q improved physical function in patients with idiopathic pulmonary fibrosis after just 3 weeks of intermittent dosing (Hickson et al., EBioMedicine, 2019).
Fisetin
A natural flavonoid found in strawberries, apples, and persimmons:
- Demonstrated potent senolytic activity in preclinical studies
- Extended healthspan and lifespan in mouse models when administered late in life
- Currently under investigation in the AFFIRM trial at the Mayo Clinic for age-related conditions
- Generally well-tolerated as a natural compound
Navitoclax (ABT-263)
A BCL-2 family inhibitor with potent senolytic activity:
- Targets the BCL-2/BCL-xL anti-apoptotic pathways that many senescent cells rely on
- Effective in preclinical models but limited by side effects (particularly platelet reduction)
- Primarily a research tool at present; not typically used in clinical longevity medicine
Other Emerging Senolytics
- FOXO4-DRI peptide: Disrupts the interaction between FOXO4 and p53 in senescent cells, releasing p53 to trigger apoptosis. Shown to restore fitness, fur density, and renal function in aged mice.
- Cardiac glycosides (ouabain, digoxin): Repurposed compounds showing senolytic activity in laboratory studies
- HSP90 inhibitors: Targeting heat shock protein 90, which senescent cells depend on for stability
How Senolytic Therapy Is Administered
The “Hit and Run” Approach
One of the most important features of senolytic therapy is that it does not require continuous dosing. Senescent cells, once cleared, take weeks to months to re-accumulate. This means senolytics can be administered in short, intermittent courses:
- Typical D+Q protocol: 3 consecutive days per month, or 3 days every 3 months
- Typical fisetin protocol: 2–3 consecutive days per month
- Treatment duration: Ongoing intermittent courses as part of a long-term longevity strategy
This intermittent dosing minimizes side effects and distinguishes senolytics from most pharmaceutical treatments that require daily administration.
Our Approach at St. George Hospital
At St. George Hospital, senolytic protocols are administered within the context of our comprehensive longevity program:
- Baseline assessment: Comprehensive diagnostic evaluation including inflammatory markers (hs-CRP, IL-6), epigenetic age testing, and functional assessments
- Patient selection: Senolytics are offered to patients with evidence of accelerated biological aging, chronic inflammation, or age-related functional decline
- Supervised administration: Senolytic courses are administered under medical supervision with laboratory monitoring
- Complementary support: Combined with NAD+ therapy, ozone therapy, and other longevity interventions for synergistic benefit
- Follow-up assessment: Repeat biomarker testing at 3–6 months to evaluate response
Research Status: What We Know and What We Don’t
Strong Evidence
- Senescent cell accumulation drives aging and age-related disease (established in multiple laboratories worldwide)
- Genetic clearance of senescent cells extends healthspan in mouse models (INK-ATTAC mouse model)
- D+Q and fisetin demonstrate senolytic activity in human cell cultures and animal models
- The first human trials have demonstrated safety and preliminary efficacy signals
What Remains to Be Established
- Long-term safety of repeated senolytic courses in humans
- Optimal dosing, timing, and combination protocols for different age-related conditions
- Whether senolytic therapy meaningfully extends human lifespan (as opposed to healthspan)
- Biomarkers for monitoring senolytic efficacy (currently there is no simple blood test to directly measure senescent cell burden)
Ongoing Clinical Trials
Major clinical trials currently underway include:
- Mayo Clinic AFFIRM trial: Fisetin for age-related conditions
- Wake Forest STAMINA trial: D+Q for bone marrow dysfunction
- Multiple trials: D+Q for diabetic kidney disease, Alzheimer’s disease, and idiopathic pulmonary fibrosis
Safety Considerations
- D+Q: Dasatinib can cause gastrointestinal side effects and, at higher doses used in oncology, blood count changes. At the low doses and intermittent schedules used for senolytic purposes, side effects are typically mild. Quercetin is a naturally occurring flavonoid with an excellent safety profile.
- Fisetin: As a natural flavonoid, fisetin has a favorable safety profile. High-dose studies are still ongoing.
- General: Because senolytic therapy is investigational, it should only be administered under medical supervision with appropriate monitoring. Self-medication is not recommended.
Frequently Asked Questions
Is senolytic therapy approved by regulatory agencies?
Senolytic therapy for aging is not currently approved as a specific medical indication by the FDA, EMA, or other regulatory bodies. Dasatinib is approved for certain leukemias, and quercetin and fisetin are available as dietary supplements. At St. George Hospital, we offer senolytic protocols within our longevity medicine program as an evidence-informed, investigational intervention with full patient informed consent and medical monitoring. We are transparent about the investigational nature of this therapy.
How will I know if senolytic therapy is working?
Improvements may be assessed through: reduction in inflammatory markers (hs-CRP, IL-6), improvement in epigenetic age testing, improved physical function (grip strength, gait speed, exercise capacity), improved metabolic markers, and subjective improvements in energy, cognitive function, and overall vitality. Because there is not yet a validated direct measure of senescent cell burden in living patients, we rely on this combination of biomarkers and functional assessments.
Can I take quercetin or fisetin on my own as a senolytic?
Quercetin and fisetin are available as over-the-counter supplements and are generally well-tolerated. However, the doses used in senolytic research are significantly higher than typical supplement doses, and the intermittent dosing protocol differs from daily supplementation. We recommend consulting with a physician experienced in longevity medicine before using these compounds at senolytic doses, particularly if you are taking other medications (quercetin, for example, can affect the metabolism of certain drugs).
Who is a good candidate for senolytic therapy?
Ideal candidates include adults over 40 with signs of accelerated biological aging, chronic low-grade inflammation, age-related functional decline, or specific conditions associated with senescent cell accumulation (joint degeneration, metabolic syndrome, persistent fatigue). Senolytic therapy is not recommended during pregnancy, in patients with severe thrombocytopenia, or in those taking specific medications that may interact with dasatinib.
How does senolytic therapy fit with other longevity interventions?
Senolytics work synergistically with other longevity interventions. Clearing senescent cells reduces the inflammatory burden, which can enhance the effectiveness of NAD+ restoration, hormone optimization, and peptide therapy. At St. George Hospital, we integrate senolytics into a comprehensive longevity protocol rather than offering them in isolation.
Explore Senolytic Therapy at St. George Hospital
If you are interested in senolytic therapy as part of a comprehensive approach to healthy aging, contact our team to discuss whether this intervention is appropriate for your situation.
Phone: +49 (0)8061 398-0
Email: info@clinicum-stgeorg.de
Location: Rosenheimer Str. 6-8, 83043 Bad Aibling, Germany
Disclaimer: Senolytic therapy for aging is an investigational approach based on compelling preclinical and early clinical evidence. It is not approved as a specific anti-aging treatment by regulatory agencies. At St. George Hospital, senolytic protocols are offered within a carefully monitored clinical framework with full informed consent. Individual results vary. This article is for educational purposes and does not constitute medical advice.
]]>